In this episode of Denatured, you’ll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hair loss space, exploring why true innovation has lagged, how a regenerative approach aims to reactivate dormant follicles and what early proof-of-concept means for patients.
> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music
In this episode of Denatured, BioSpace’s Jennifer C. Smith- Parker is joined by Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly.
They explore the long-overlooked hair loss space, unpacking why innovation has been limited, how regenerative strategies aim to reactivate dormant follicles and what early proof-of-concept could mean for patients.
Host
Jennifer C. Smith-Parker, Director of Insights, BioSpace
Guests
Daniel Gil, CEO, Pelage Pharmaceuticals
Francisco Ramírez-Valle, Senior Vice President, Immunology Discovery, Eli Lilly
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
